<DOC>
	<DOCNO>NCT01304836</DOCNO>
	<brief_summary>The purpose study focus potential difference occurrence new-onset Diabetes Mellitus ( glucose metabolism disorder ) two different regimen immunosuppressive treatment compare .</brief_summary>
	<brief_title>A Study Looking Diabetes Kidney Transplant Recipients Receiving Immunosuppressive Regimen With Without Steroids</brief_title>
	<detailed_description>The primary objective study compare Immunosuppressive regimen 10 day corticosteroid regimen optional intra-op bolus corticosteroid regard incidence new onset Diabetes Mellitus per American Diabetic Association ( ADA ) criteria point 24 week kidney transplantation .</detailed_description>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>End stage kidney disease suitable candidate primary kidney transplantation retransplantation ( unless graft lose rejection within one year ) Receiving kidney transplant decease living ( non Human Leukocyte Antigen identical ) donor compatible AB0 blood type Female subject childbearing potential must negative serum urine pregnancy test enrollment must agree maintain highly effective birth control study . A highly effective method birth control define result low failure rate ( CPMP/ICH/286/95 modify ) less 1 % per year use consistently correctly implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomize partner Receiving previously receive organ transplant kidney Cold ischemia time donor kidney &gt; 30 hour Panel Reactive Antibody &gt; 20 % ( Highest level 6 month prior transplant ) Previous renal transplant lose within one year immunological reason Receiving graft nonheartbeating donor Maastricht category 3 ( withdrawal support await cardiac arrest ) Significant liver disease , define continuously elevate SGPT/ALT and/or SGOT/AST and/or total bilirubin level ≥ 2 time upper value normal range investigational site receive graft hepatitis C B positive donor Diagnosis Diabetes Mellitus prior transplantation ( treat prescribe medication diet control ) evidence previous positive Oral Glucose Tolerance Test ( OGTT ) patient medical history previous diagnosis gestational diabetes prebaseline HbA1C ≥6.5 % Requiring initial sequential parallel therapy immunosuppressive antibody preparation ( ) . Requiring ongoing dose systemic immunosuppressive drug prior transplantation ( e.g . Lupus Disease , FSGN etc ) minimal level immunosuppressant follow failure previous transplantation without nephrectomy Where Physician considers long term steroid treatment necessary prevention recurrent auto immune mediate renal disease subject require ongoing dose corticosteroid study condition Significant , uncontrolled concomitant infection and/or severe diarrhea , vomit , active upper gastrointestinal tract malabsorption active peptic ulcer Pregnant woman breastfeed mother Subject donor know HIV positive Known allergy intolerance tacrolimus , macrolide antibiotic , corticosteroid , basiliximab , mycophenolate mofetil product excipients Evidence malignant disease within last 5 year Basal Cell Carcinoma Squamous Cell Carcinoma Currently participate another clinical trial and/or take investigational drug within 28 day prior randomization Any form substance abuse , psychiatric disorder condition , opinion investigator , may complicate communication investigator Unlikely comply visit schedule protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Transplant</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Diabetes Mellitus</keyword>
</DOC>